Comparison of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of GZR101-80 Injection With Separately Injected, Simultaneous Doses of GZR33 Injection and Insulin Aspart

October 31, 2026 updated by: Gan & Lee Pharmaceuticals.

A Phase I Study Comparing Pharmacokinetic/Pharmacodynamic Characteristics and Safety of Single Administration of GZR101-80 Injection With Separately Injected, Simultaneous Doses of GZR33 Injection and Insulin Aspart in Healthy Participants

This trial is conducted in China. This study will be conducted to evaluate pharmacokinetic/pharmacodynamic characteristics and safety of single administration of GZR101-80 Injection with separately injected, simultaneous doses of GZR33 Injection and Insulin Aspart in healthy participants

Study Overview

Study Type

Interventional

Enrollment (Estimated)

26

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  1. Voluntarily signed the informed consent form (ICF), was amenable to subcutaneous injection, had fully understood the study content, procedures and potential adverse reactions, and was able to comply with the contraindications and restrictions specified in this protocol.
  2. Male, aged between 18 and 45 years (both inclusive) at the time of ICF.

Exclusion Criteria:

  1. Subjects with allergic diathesis, or a medical history of allergic diseases such as bronchial asthma and eczema.
  2. Subjects with abnormal findings for hepatitis B surface antigen, hepatitis C antibody, human immunodeficiency virus antigen and antibody combined assay, or treponema pallidum antibody test at screening.
  3. Subjects who donated blood or had blood loss of ≥ 400 mL within 6 months prior to screening, or intend to donate blood during the study.
  4. Subjects with a history of drug abuse prior to screening, or with a positive drug abuse screening result at screening.
  5. Subjects with an average daily cigarette consumption of ≥5 cigarettes within 3 months prior to screening, or those who refuse to abstain from smoking throughout the study period.
  6. Subjects with a history of vasovagal syncope related to needles or blood, difficulty in blood collection, or intolerance to venipuncture for blood sampling.
  7. Subjects who are employees of the investigator or the study site, or family members of such employees or investigators, or subjects whom the investigator considers otherwise unsuitable for participation in this study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: GZR101 80 Injection

Single dose. Administered s.c.

Experimental: GZR33 Injection + Insulin Aspart Injection

Single dose. Administered s.c.

Single dose. Administered s.c.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
AUCIAsp,0-6h
Time Frame: 0-6 hours after dosing
0-6 hours after dosing
AUC GZR33, 0-24h
Time Frame: 0-24 hours after dosing
0-24 hours after dosing

Secondary Outcome Measures

Outcome Measure
Time Frame
AUCGZR33, 0-∞
Time Frame: 0-120 hours after dosing
0-120 hours after dosing
AUC IAsp, 0-∞
Time Frame: 0-120 hours after dosing
0-120 hours after dosing
Incidence of adverse events
Time Frame: 0-120 hours after dosing
0-120 hours after dosing

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

October 29, 2026

Primary Completion (Estimated)

February 2, 2027

Study Completion (Estimated)

February 2, 2027

Study Registration Dates

First Submitted

October 27, 2026

First Submitted That Met QC Criteria

October 31, 2026

First Posted (Actual)

November 5, 2026

Study Record Updates

Last Update Posted (Actual)

November 5, 2026

Last Update Submitted That Met QC Criteria

October 31, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe